Medical Innovation Exchange

Lace To Helm New RQM+ Reimbursement Division



RQM+, a global MedTech regulatory and quality service provider, has launched a reimbursement division to provide its clients with reimbursement services, in addition to regulatory, quality, clinical and laboratory services, throughout the medical device and diagnostics product lifecycle. Daniel Lace, MD, will lead the new division and serve as chief medical officer (CMO) of RQM+.

Dr. Lace has more than 25 years of leadership experience as a healthcare executive across a wide range of managed care, pharmaceutical, device, diagnostic and consulting businesses. He has served as CMO and has held senior leadership positions in global pharmaceutical and medical device companies, as well as national managed care organizations.

“MedTech manufacturers are seeking reimbursement partners to manage increasingly complex challenges and ensure that reimbursement strategies are developed in tandem with regulatory strategies,” said Margaret Keegan, CEO of RQM+. “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”

“It is a privilege to serve as CMO—providing strategic guidance for reimbursement as well as related services and technologies,” said Dr. Lace. “We look forward to helping customers navigate the complicated reimbursement and market access environment. We will use our extensive experience with the latest reimbursement requirements and value-based compensation models, as well as key payment trends, to provide customized support that fits each company’s needs.”


Related Articles

  • The Appeals Process

    Presenting clinical evidence to payers is the most efficient method of gaining coverage. But when this strategy is unsuccessful or hits a wall, a ground-up approach is required, relying on consistent and steady support from local physician champions that demonstrates…

  • Let's Start at the Very Beginning

    No matter how tortuous the path to durable coverage and adequate payment for a new technology, the bedrock of the entire reimbursement process relies on the clinical evidence of safety and effectiveness. This inaugural blog post is the first in…

  • Humanitarian Use Devices and Third-Party Reimbursement

    Payers often apply the same evidence standards to Humanitarian Use Devices as other devices and demand high quality clinical trials, following an approach similar to the PMA or 510(k) regulatory pathways, where payers frequently impose a higher evidence standard than…

  • Done – Medtronic-Covidien Deal

    Medtronic has completed the 50 billion acquisition of Covidien, in the largest medical device merger of all time.


Original post:

Post publish date:


Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!